A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-09

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from starting dose level 1: 1×10\^6 (±20%) to dose level 2: 2×10\^6 (±20%) in three cohorts (autologous, previous-transplant-donor or newly matched donor-derived CD5 CAR T cells). If the manufactured cells are not sufficient to meet the preassigned standard dose criteria, patients will be given infusion at a low dose level of 5×10\^5 (±20%) /kg. The primary objective is to evaluate the safety and tolerability of CD5 CAR T cell therapy in subjects, determine the OBD and recommend phase 2 dose (RP2D) in phase 1, and evaluate the efficacy of CD5 CAR T cell therapy in phase 2. The primary endpoint is the type and incidence of dose-limiting toxicity (DLT) within 28 days, and the incidence and severity of adverse events (AEs) within 30 days after CD5 CAR T-cell infusion in phase 1, the best overall response (BOR) at 3 months (± 1 week) after CD5 CAR T-cell infusion in phase 2. A total number of 54 subjects will be enrolled.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

NCT06316856

T-Cell Acute Lymphocytic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia +1 more

RECRUITING PHASE1/PHASE2

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

NCT06316427

T-cell Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia +1 more

RECRUITING PHASE1/PHASE2

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

NCT06420076

T Cell Lymphoma T Cell Leukemia T-cell Acute Lymphoblastic Leukemia +3 more

RECRUITING PHASE1/PHASE2

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

NCT07022964

T-Cell Non-Hodgkin Lymphoma T-cell Lymphoma (PTCL and CTCL)

RECRUITING PHASE1/PHASE2

Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

NCT06696833

B-Cell Acute Lymphoblastic Leukemia, Adult

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

详细描述

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

T-Cell Acute Lymphocytic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia T-cell Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autologous CD5 CAR T-cells

After a lymphodepleting regimen, the patients will receive autologous CD5 CAR T-cell infusion.

Group Type EXPERIMENTAL

Autologous CD5 CAR T-cells

Intervention Type DRUG

Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.

Prior stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells

After a lymphodepleting regimen, the patients will receive prior SCT donor-derived CD5 CAR T-cell infusion.

Group Type EXPERIMENTAL

Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells

Intervention Type DRUG

Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.

Newly matched donor-derived CD5 CAR T-cells

After a lymphodepleting regimen, the patients will receive newly matched donor-derived CD5 CAR T-cell infusion

Group Type EXPERIMENTAL

Newly matched donor-derived CD5 CAR T-cells

Intervention Type DRUG

Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous CD5 CAR T-cells

Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.

Intervention Type DRUG

Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells

Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.

Intervention Type DRUG

Newly matched donor-derived CD5 CAR T-cells

Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Only patients who meet all the following criteria can be included:

1\. Candidates with relapse or refractory CD5+ T-cell malignancies, who have progressed after treatment with all standard therapies or been intolerant of standard care, have limited prognosis with currently available therapies and have no available curative treatment options (such as stem-cell transplantation (SCT) or chemotherapy); 2. For subjects who received autologous CD5 CAR T cells, the tumor burden in peripheral blood is less than 20%, and suspending anti-neoplastic treatment for more than 2 weeks; 3. Aged 1-70 years; 4. No severe allergy; 5. Eastern Cooperative Oncology Group (ECOG) performance status 1 score 0 to 2; 6. Patients are expected to live for at least 60 days; 7. CD5+ on blasts in bone marrow (BM) or cerebrospinal fluid (CSF) and tumor tissues by flow cytometry and immunohistochemistry, respectively. (Positive rate \>80% by flow cytometry with less than one log difference in mean fluorescence intensity from normal T cells, or positive rate \>30% positive by immunohistochemistry); 8. Provide a signed informed consent before any screening procedure. Subjects who voluntarily participate in the study should have the ability to understand and sign the informed consent form and be willing to follow the study visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19-70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. Children candidates of 8-18 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form and their legal guardian or patient advocate has also need to sign the treatment consent form and voluntary consent form, respectively. Children candidates of 1-7 can be recruited after the legal guardian or patient advocate has signed the treatment consent form and voluntary consent form; 9. Have available allogeneic hematopoietic stem cell transplantation donor for the subject who received newly matched donor-derived CD5 CAR T cells, and is willing to perform SCT when CR is achieved.

\-

Exclusion Criteria

Patients with at least one of the following conditions are excluded:

1\. Impaired consciousness or intracranial hypertension; 2. Symptomatic congestive heart failure or severe cardiac arrhythmia; 3. Manifestations of severe respiratory system failure; 4. Co-existence with other malignancies; 5. Disseminated intravascular coagulation; 6. Serum creatinine and/or blood urea nitrogen (BUN) ≥ 1.5-fold upper limit; 7. Sepsis or other uncontrollable infections; 8. Uncontrollable diabetes; 9. Serious mental illness; 10. Apparent and active intracranial lesions on cranial magnetic resonance imaging (MRI); 11. Underwent organ transplantation, excepting SCT; 12. Pregnant females; 13. Positive test for infectious hepatitis, acquired immune deficiency syndrome (AIDS) or syphilis; 14. Post-CAR SCT is not feasible in patients who plan to receive newly matched donor-derived CD5 CAR T cells; 15. Inability to collect peripheral blood mononuclear cells (PBMC) or no frozen PBMC available for CAR T cell manufacturing.

\-

Minimum Eligible Age

1 Year

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No